Clinical Trial Update: Nintedanib(BIBF1120) in Thyroid Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of nintedanib (BIBF1120) in thyroid cancer (medullary and differentiated thyroid cancer) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Differentiated Thyroid Cancer
• Medullary Thyroid Carcinoma

Drugs mentioned

• Nintedanib (nintedanib)

Snippet

Sponsor: European Organisation for Research and Treatment of Cancer - EORTC | Conditions: Medullary Thyroid Cancer (MTC), Differentiated Thyroid Cancer (DTC) | Phase 2 | Status: COMPLETED